{"id":"liraglutide-exercise-training","safety":{"commonSideEffects":[{"rate":"20-40","effect":"Nausea"},{"rate":"5-15","effect":"Vomiting"},{"rate":"10-20","effect":"Diarrhea"},{"rate":"10-20","effect":"Constipation"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Hypoglycemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Liraglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1, stimulating insulin release in response to glucose and suppressing glucagon secretion, thereby lowering blood glucose. Combined with structured exercise training, which independently improves insulin sensitivity, glucose utilization, and cardiovascular health, this combination approach addresses multiple pathways in metabolic disease management.","oneSentence":"Liraglutide activates GLP-1 receptors to enhance insulin secretion and reduce appetite, while exercise training improves insulin sensitivity and cardiovascular fitness through physical conditioning.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:34:07.661Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus (in combination with exercise training)"},{"name":"Weight management in obesity (in combination with exercise training)"}]},"trialDetails":[{"nctId":"NCT04575844","phase":"PHASE4","title":"Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome","status":"RECRUITING","sponsor":"University of Virginia","startDate":"2020-11-01","conditions":"Metabolic Syndrome","enrollment":80},{"nctId":"NCT04122716","phase":"PHASE4","title":"Combined Effects of GLP-1 Analogue and Exercise on Maintenance of Weight Loss and Health After Very-low Calorie Diet","status":"UNKNOWN","sponsor":"Signe Torekov","startDate":"2016-09","conditions":"Obesity","enrollment":215},{"nctId":"NCT01455441","phase":"PHASE4","title":"The Effects of Physical Training and GLP-1 Receptor Agonist Liraglutide Treatment in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tina Vilsboll","startDate":"2011-10","conditions":"Type 2 Diabetes","enrollment":40},{"nctId":"NCT01974544","phase":"NA","title":"Prevention and Treatment Of Diabetes Complications With Gastric Surgery or Intensive Medicines","status":"UNKNOWN","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2013-05","conditions":"Type 2 Diabetes","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Liraglutide + Exercise training","genericName":"Liraglutide + Exercise training","companyName":"University of Virginia","companyId":"university-of-virginia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Liraglutide, a glucagon-like peptide 1 receptor agonist, has been studied in combination with exercise training for conditions such as Type 2 Diabetes, Metabolic Syndrome, and Obesity. The combination of liraglutide and exercise training has been investigated in clinical trials to improve metabolic response in patients with these conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}